<SEC-DOCUMENT>0001193125-22-258527.txt : 20221006
<SEC-HEADER>0001193125-22-258527.hdr.sgml : 20221006
<ACCEPTANCE-DATETIME>20221006064929
ACCESSION NUMBER:		0001193125-22-258527
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221006
FILED AS OF DATE:		20221006
DATE AS OF CHANGE:		20221006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221297083

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d403364d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October&nbsp;6, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d403364dex991.htm">Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 6, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d403364dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g403364g38p27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Abstracts Accepted for Presentation at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Initial data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial treating patients with various solid tumours with triple
combination therapy of efti, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and chemotherapy to be discussed at SITC </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 06 October </B><B>2022</B><B> &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, will announce first interim data from the <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> clinical trial in a poster
presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022, which is taking place in person in Boston, US and virtually from 8 to 12&nbsp;November 2022. A <I>Trial in Progress</I> poster on the phase IIb <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> trial will also be presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phase I <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial is the
first trial evaluating Immutep&#146;s lead product candidate, eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) as part of a triple combination therapy consisting of efti and an approved standard of care combination of chemotherapy and an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. The trial is recruiting up to 20 patients with various solid tumours, focusing on NSCLC adenocarcinomas. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> Abstract</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B><B><I> </I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Feasibility of eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein) combined with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care-therapy</FONT></FONT> in advanced <FONT
STYLE="white-space:nowrap">non-small-cell</FONT> lung cancer (NSCLC) adenocarcinomas. Initial results from INSIGHT 003</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Poster display session:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Friday, Nov 11, 2022; 9 am &#150; 9 pm EST</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenter:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr.<B></B>&nbsp;Akin Atmaca</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U><FONT STYLE="white-space:nowrap">TACTI-003</FONT> </U></B><B><I><U>Trial in Progress</U></I></B><B><U> Abstract</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B><B><I> </I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I><FONT STYLE="white-space:nowrap">TACTI-003:</FONT> A randomized Phase IIb study of eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein) and pembrolizumab as first-line treatment of patients with
recurrent or metastatic head and neck squamous cell carcinoma</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Poster display session:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Thursday, November&nbsp;10, 2022; 9 am &#150; 8:30 pm EST</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenter:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr.&nbsp;Irene Bra&ntilde;a</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep also has a Late Breaking Abstract accepted at SITC 2022. Titles for Late Breaking Abstracts will become publicly
available on 2&nbsp;November 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SITC 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SITC is the world&#146;s leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and
application of cancer immunotherapy. The SITC Annual Meeting is the largest conference solely focused on cancer immunotherapy and brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and
educate the world on cancer immunotherapy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g403364g38p27.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for
the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT>
fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple
clinical trials. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune
response modulation, are licensed to and being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the
Company&#146;s <U>website www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) 679 9282;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited, Marc Voigt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g403364g38p27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g403364g38p27.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !Q S$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"EXB\1V/A'0[K4M3NH+&PL8FFGGF;:D2#J2:^5O'/_!533;76WM?#'A6\
MUB!7V)<W5Q]F\\]/DC"LV#VS@^U7/^"F?Q&308/!.@WL5S<Z%J%\U_JUM!+Y
M3WL,)3$0?MDN3]0I[5RO[*G['W@SXXSW/CJUNM?TW18]28:9I2RJDUD\1!.^
M;+%QG&W&#CJ37EXC$5I5?8T-UN?)YEF.-JXSZE@&DUOWVOUTLM/.YZ7\"O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$_
M_!6/_D:/!/\ UZWG_H<->L:!_P HVQ_V)DG_ *(:O)_^"L?_ "-'@G_KUO/_
M $.&O6- _P"4;8_[$R3_ -$-7CK_ 'FMZ?HCXNG_ ,C3&?X/T1X[_P $GO\
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M^A6U?K5XK\):9XZ\/76E:S86FIZ;>QF*>VN8A)'*IX((/%?D+^U-XGM/!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\31_PI'P9_T*7AG_ ,%<'_Q-'U'$_P#/W\P_L+-/^@M_C_F?!?\ P\I^*/\
MT$]#_P#!<G^-'_#RGXH_]!/0_P#P7)_C7WI_PI'P9_T*7AG_ ,%<'_Q-'_"D
M?!G_ $*7AG_P5P?_ !-'U'$_\_?S#^PLT_Z"W^/^9\%_\/*?BC_T$]#_ /!<
MG^-'_#RGXH_]!/0__!<G^-?>G_"D?!G_ $*7AG_P5P?_ !-'_"D?!G_0I>&?
M_!7!_P#$T?4<3_S]_,/["S3_ *"W^/\ F?!?_#RGXH_]!/0__!<G^-'_  \I
M^*/_ $$]#_\ !<G^-?>G_"D?!G_0I>&?_!7!_P#$T?\ "D?!G_0I>&?_  5P
M?_$T?4<3_P _?S#^PLT_Z"W^/^9\%_\ #RGXH_\ 03T/_P %R?XT?\/*?BC_
M -!/0_\ P7)_C7WI_P *1\&?]"EX9_\ !7!_\31_PI'P9_T*7AG_ ,%<'_Q-
M'U'$_P#/W\P_L+-/^@M_C_F?!?\ P\I^*/\ T$]#_P#!<G^-'_#RGXH_]!/0
M_P#P7)_C7WI_PI'P9_T*7AG_ ,%<'_Q-'_"D?!G_ $*7AG_P5P?_ !-'U'$_
M\_?S#^PLT_Z"W^/^9\%_\/*?BC_T$]#_ /!<G^-'_#RGXH_]!/0__!<G^-?>
MG_"D?!G_ $*7AG_P5P?_ !-'_"D?!G_0I>&?_!7!_P#$T?4<3_S]_,/["S3_
M *"W^/\ F?!?_#RGXH_]!/0__!<G^-'_  \I^*/_ $$]#_\ !<G^-?>G_"D?
M!G_0I>&?_!7!_P#$T?\ "D?!G_0I>&?_  5P?_$T?4<3_P _?S#^PLT_Z"W^
M/^9\%_\ #RGXH_\ 03T/_P %R?XT?\/*?BC_ -!/0_\ P7)_C7WI_P *1\&?
M]"EX9_\ !7!_\31_PI'P9_T*7AG_ ,%<'_Q-'U'$_P#/W\P_L+-/^@M_C_F?
M!?\ P\I^*/\ T$]#_P#!<G^-'_#RGXH_]!/0_P#P7)_C7WI_PI'P9_T*7AG_
M ,%<'_Q-'_"D?!G_ $*7AG_P5P?_ !-'U'$_\_?S#^PLT_Z"W^/^9\%_\/*?
MBC_T$]#_ /!<G^-'_#RGXH_]!/0__!<G^-?>G_"D?!G_ $*7AG_P5P?_ !-'
M_"D?!G_0I>&?_!7!_P#$T?4<3_S]_,/["S3_ *"W^/\ F?!?_#RGXH_]!/0_
M_!<G^-'_  \I^*/_ $$]#_\ !<G^-?>G_"D?!G_0I>&?_!7!_P#$T?\ "D?!
MG_0I>&?_  5P?_$T?4<3_P _?S#^PLT_Z"W^/^9\%_\ #RGXH_\ 03T/_P %
MR?XT?\/*?BC_ -!/0_\ P7)_C7WI_P *1\&?]"EX9_\ !7!_\31_PI'P9_T*
M7AG_ ,%<'_Q-'U'$_P#/W\P_L+-/^@M_C_F?!?\ P\I^*/\ T$]#_P#!<G^-
M'_#RGXH_]!/0_P#P7)_C7WI_PI'P9_T*7AG_ ,%<'_Q-'_"D?!G_ $*7AG_P
M5P?_ !-'U'$_\_?S#^PLT_Z"W^/^9\%_\/*?BC_T$]#_ /!<G^-'_#RGXH_]
M!/0__!<G^-?>G_"D?!G_ $*7AG_P5P?_ !-'_"D?!G_0I>&?_!7!_P#$T?4<
M3_S]_,/["S3_ *"W^/\ F?!?_#RGXH_]!/0__!<G^-'_  \I^*/_ $$]#_\
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M\31_PI'P9_T*7AG_ ,%<'_Q-'U'$_P#/W\P_L+-/^@M_C_F?!?\ P\I^*/\
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M3_S]_,/["S3_ *"W^/\ F?!?_#RGXH_]!/0__!<G^-'_  \I^*/_ $$]#_\
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M\31_PI'P9_T*7AG_ ,%<'_Q-'U'$_P#/W\P_L+-/^@M_C_F?!?\ P\I^*/\
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M**]#V<^Y]-["M_.7:***W.P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
